Clinical trials: Emergency Patients
Hemorrhage
CU Programme of Idarucizumab for Japanese Patients
The objective is to collect the safety data of idarucizumab for patients treated with dabigatran who require rapid reversal of the anticoagulant effects of dabigatran in cases of uncontrolled or life-threatening bleeding or when…
- Trial name
- NCT02831660
- Testing
- idarucizumab
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
Moderate-to-severe Acute Pain
Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain
To evaluate the safety and efficacy of sufentanil tablet (ST) 30 mcg in the management of moderate-to-severe acute pain in patients in an emergency room (ER) setting.
- Trial name
- NCT02447848
- Testing
- sufentanil sublingual 30 mcg tablet
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Talphera, Inc
Shortness of Breath Episode, Tachycardia
Verification of Prediction Algorithm
Prospective observational clinical study to verify an algorithm used to predict cardiopulmonary events in patients presenting to the emergency department.
- Conditions
- Shortness of Breath Episode, Tachycardia, Bradycardia, Difficulty Breathing
- Trial name
- VPAC (NCT02863666)
- Where
- 3 sites in United States, Belgium
- Volunteers
- 673 people
- Sponsor
- Zoll Medical Corporation
Nervous System Diseases
Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan
The purpose of this study is to assess the efficacy, safety and pharmacokinetics of MHOS/SHP615 administered buccally in children with status epilepticus (convulsive) in a healthcare setting.
- Trial name
- NCT03336645
- Testing
- SHP615
- Where
- 23 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Shire
Atrial Fibrillation
Medical Need of OAC Reversal
This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF
- Trial name
- NCT03254147
- Testing
- warfarin, dabigatran, Apixaban
- Where
- Japan
- Volunteers
- 53,969 people
- Sponsor
- Boehringer Ingelheim
Abscess
The Effect of Wound Irrigation With Irrisept on Abscess Healing (Irrisept UF Study)
The purpose of this study was to evaluate the safety and effectiveness of Irrisept compared to standard of care treatment of skin and soft tissue infections in the form of abscesses.
- Trial name
- NCT04957732
- Testing
- Standard of Care (SoC), Irrisept Delivery System
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Irrimax Corporation
Heart Failure
Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure
The study is to evaluate the safe admission avoidance and the overall economic impact associated with management of worsening HF using the drug-device combination product, the Furoscix Infusor, outside the hospital setting in…
- Trial name
- FREEDOM-HF (NCT03458325)
- Testing
- Furoscix Infusor
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- scPharmaceuticals, Inc.
Candidiasis, Invasive, Candidemia
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
This is a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy, safety, tolerability and PK (pharmacokinetics) of oral SCY-078 as an emergency use treatment for patients with a documented Candida…
- Trial name
- CARES (NCT03363841)
- Testing
- SCY-078
- Where
- 12 sites in United States, India and 2 more
- Volunteers
- 30 people
- Sponsor
- Scynexis, Inc.
Hemorrhage
Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
Evaluate the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
- Trial name
- NCT02104947
- Testing
- idarucizumab
- Where
- 176 sites in United States, Argentina and 31 more
- Volunteers
- 503 people
- Sponsor
- Boehringer Ingelheim
Carbon Monoxide Poisoning, Anemia
Utility of Non-invasive Carboxyhemoglobin and Total Hemoglobin Measurement in the Emergency Department
The purpose of this study is to determine the clinical utility of triage screening for anemia and carbon monoxide poisoning (COP) in the ED setting.This is a prospective, nonrandomized, multi-center study of the performance of…
- Trial name
- NCT03017742
- Testing
- Pulse Oximeter
- Where
- Turkey (Türkiye)
- Volunteers
- 813 people
- Sponsor
- Masimo Corporation
Vascular Access Complication
Prospective Feasibility Trial of AccuCath 2.25" Blood Control (BC) Placed in Difficult Access Patients in the Emergency Department
Study objective is to evaluate user preference, time for procedure, insertion success rates, complications, completion of therapy and dwell time of the AccuCath 2.25" BC device placed in difficult IV access patients in the…
- Trial name
- NCT02449798
- Testing
- AccuCath 2.25" BC Intravascular Catheter
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- C. R. Bard
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation
Hemorrhage
This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding
The primary objective is to demonstrate reversal of the anticoagulant effect of dabigatran in patients treated with dabigatran etexilate who have uncontrolled or life-threatening bleeding requiring urgent intervention, and in…
- Trial name
- NCT03343704
- Testing
- Idarucizumab
- Where
- 13 sites in China
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim